PTAB Won't Review Suboxone IP After Teva Misses Deadline
Teva Pharmaceuticals was too late to challenge two Suboxone patents, the Patent Trial and Appeal Board ruled Monday, despite the drugmaker's claim that technical issues with the board's online filing system...To view the full article, register now.
Already a subscriber? Click here to view full article